PGP and neoplasm: Patients with EGFR activating mutations are initially effective on tyrosine kinase inhibitor (TKI) therapy, such as gefitinib, but often develop acquired resistance.P‐gp is a membrane transporter protein encoded by the MDR1 gene that is widely expressed in tumor cells.